Skip to Content
Merck
CN
  • [Relationship between G6PD deficiency and hand-foot-mouth disease induced by enterovirus 71].

[Relationship between G6PD deficiency and hand-foot-mouth disease induced by enterovirus 71].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics (2013-09-17)
Jun-Bin Ou, Cui-Mei Zhang, Si-Mao Fu, Xiang Huang, Lian-Hong Huang
ABSTRACT

To study the influence of glucose-6-phosphate dehydrogenase (G6PD) deficiency on hand-foot-mouth disease (HFMD) induced by enterovirus 71 (EV71) , and possible mechanisms. A total of 220 boys with HFMD induced by EV71 were classified into two groups based on disease severity: mild/moderate (n=145) and severe HFMD groups (n=75), and 132 healthy boys were selected as the control group. The activity of G6PD and levels of reduced glutathione (GSH) and malonaldehyde (MDA) in blood were measured using the automatic biochemical analyzer. The percentage of G6PD deficiency cases in the severe HFMD group was significantly higher than in the control group (P<0.0125). In the severe HFMD group, the durations of fever, mental abnormality, limb trembling and hospital stay were significantly longer in children with G6PD deficiency than in those with normal G6PD activity (P<0.05). In the acute and recovery stages, patients in the mild/moderate and severe HFMD groups had significantly lower GSH levels and G6PD activity and significantly higher MDA levels compared with those in the control group (P<0.05). In the acute stage, children in the mild/moderate and severe HFMD groups with G6PD deficiency had significantly lower GSH levels and significantly higher MDA levels compared with those with normal G6PD activity (P<0.01). In the acute and recovery stages, GSH level in children with HFMD was positively correlated with G6PD activity (r=0.61, P<0.01; r=0.58, P<0.01), and in the acute stage, MDA level was negatively correlated with G6PD activity (r=-0.29, P<0.01). G6PD deficiency is probably a predisposing factor for HFMD induced by EV71 and may aggravate the patient's condition. Its mechanism might be related to oxidative stress.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from baker′s yeast (S. cerevisiae), Type XV, lyophilized powder, 200-400 units/mg protein (modified Warburg-Christian)
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from baker′s yeast (S. cerevisiae), Type IX, lyophilized powder, 200-400 units/mg protein (modified Warburg-Christian)
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from baker′s yeast (S. cerevisiae), Type VII, ammonium sulfate suspension, ≥200 units/mg protein
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from Leuconostoc mesenteroides, lyophilized powder, >= 550 units/mg protein (biuret)
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from Leuconostoc mesenteroides, recombinant, expressed in E. coli, lyophilized powder, ≥550 units/mg protein (biuret)
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from Leuconostoc mesenteroides, recombinant, expressed in E. coli, ammonium sulfate suspension, ≥550 units/mg protein (biuret)
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from Leuconostoc mesenteroides, Type XXIII, ammonium sulfate suspension, 550-1,100 units/mg protein (biuret), ≥2.0 mg/mL Biuret